A testing system includes a well cover portion, a sensor portion extending from the well cover portion, a sensing surface disposed on the sensor portion, a conducting wire extending through the sensor portion and contacting the sensing surface, a transducer connected to the conducting wire, and a reference electrode extending through the well cover portion.

The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of an Nrf2-inhibitor.

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

The present invention provides, among other things, improved substrate clearance assays for lysosomal enzyme that are particularly useful for measuring potency of lysosomal enzymes or other therapeutics for treatment of lysosomal storage diseases. In particular, the present invention combines a physiologically relevant substrate cell assay and an efficient scintillation based detection method.

Systems, devices and methods for cell analysis provide an end user with real-time cell analysis and imaging of single cells in a population. Various cell analysis systems can provide both optical imaging, as well as electroscopic imaging, which is an image of cellular response as detected by sensors covering a cell footprint or cellular efflux. An automated fluidic system can provide an end-user selected sequence of reagents to cells, while precision controlled sensor array device thermostatting, and analysis compartment environmental control provide consistency in the cell analysis system environment.

This disclosure relates to biomarkers for Age-Related Macular Degeneration (AMD) and methods of use thereof, e.g., methods of the use of biomarkers for determining that a subject has Age-related Macular Degeneration (AMD) or determining the stage of AMD in a subject.

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

Provided herein are methods, pharmaceutical compositions, and kits for treating and/or preventing a viral infection resulting from a coronaviridae family virus in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I). Further provided herein are methods for inhibiting the viral entry into a cell of a coronaviridae family virus (e.g., alpha-coronavirus (e.g., HCoV-NL63, HCoV-229E), betacoronavirus (e.g., SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-OC43, HCoV-HKU1)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a viral infection resulting from a coronaviridae family virus in a subject in need thereof.

##STR00001##

Embodiments disclosed herein relate to apparatuses, systems, and methods for detecting biomarkers in biological samples present in assay tests using a control strip and indicator strip, where the control strip includes reagents that form a reactive gas which reacts with the biomarker on the indicator strip, if present. Methods of using the test apparatuses include taking a sending photographs of a used test apparatus to a medical provider to demonstrate adherence to a pharmaceutical treatment regimen.

Provided are non-NHE3-binding agents having activity as phosphate transport/uptake inhibitors in the gastrointestinal tract, including in the small intestine, methods for their use as therapeutic or prophylactic agents, and related methods of drug discovery.